Clinical Trial Detail

NCT ID NCT02778685
Title Pembrolizumab, Letrozole, and Palbociclib in Treating Patients With Stage IV Estrogen Receptor Positive Breast Cancer With Stable Disease That Has Not Responded to Letrozole and Palbociclib
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements yes
Sponsors City of Hope Medical Center
Indications

Her2-receptor negative breast cancer

Therapies

Letrozole + Palbociclib + Pembrolizumab

Age Groups: adult

Additional content available in CKB BOOST